전체 8345
-
- 2010 NIH Symposium in Neurobiology-A Tribute to Marshall W. Nirenberg
-
- - Gottesman, Balaban, Peterkofsky, Rovescalli, Greene, Catterall, Breakefield, Odenwald, Szyf, Scolnick and Barondes (2010/11/18)
- - Category : Conferences
- Dr. Nirenberg made numerous contributions in Neuroscience that have been pivotal for advancing our knowledge in such fields as neural adhesion molecules, neural differentiation, opiate receptors and morphine tolerance, voltage-dependent calcium channels, and, more recently, homeobox genes and the development of the embryonic nervous system. In his career as a neuroscientist, Dr. Nirenberg published seminal papers, and mentored researchers who later became prominent neuroscientists, and he used virtually every innovative technique that would help quench his constant thirst for good answers and better questions.
This symposium will pay tribute to Dr. Nirenberg？？？s research and contributions in the field, featuring talks by prominent neuroscientists who trained in his laboratory, as well as colleagues who share his passion and efforts to understand the biological basis underlying the development and function of the nervous system.
Michael Gottesman, DDIR, OD, NIH;
Robert S. Balaban, NHLBI, NIH;
Alan Peterkofsky, NHLBI, NIH;
Alessandra Rovescalli, NHLBI, NIH;
Lloyd Greene, Columbia University Medical Center, New York, NY;
William Catterall, University of Washington, Seattle, WA;
Xandra Breakefield, Massachusetts General Hospital Neuroscience Center, Charlestown, MA;
Ward Odenwald, NINDS, NIH;
Moshe Szyf, Faculty of Medicine, McGill University, Montreal, Canada;
Edward Scolnick, Stanley Center for Psychiatric Research, Broad Institute, MIT, Boston MA;
Samuel Barondes, Center for Neurobiology and Psychiatry, University of California School of Medicine, San Francisco, CA.
2010 NIH Symposium in Neurobiology-A Tribute to Marshall W. Nirenberg
-
- Marshall Nirenberg Memorial Service
-
- - Robert Balaban (2010/11/18)
- - Category : Special
- Tribute and Memorial Service to Dr. Marshall Nirenber
Marshall Nirenberg, M.D., was a noted geneticist and winner of the 1968 Nobel Prize for Physiology or Medicine. He was the first NIH scientist to receive this honor.
Dr. Nirenberg, with co-winners Robert W. Holley and Har Gobind Khorana, was awarded the Nobel Prize in recognition for their interpretation of the genetic code and its function in protein synthesis. The world marveled as their work created a body of knowledge that forever changed human health, creating an explosion in the field of human genetics, and emphasizing the unity of all living things by their shared use of the same code. Marshall？？？s wish to explore turned into a revelation about biology that is almost unmatched in terms of its consequences for understanding of life.
Dr. Nirenberg also espoused many causes over his lifetime and recognized the important role played by science and scientists in society. With others, he propelled scientists to prominence as social and humanitarian advocates, not just in the prevention and treatment of disease, but as members of the world community at large, concerned with technology, the environment, politics, and economics.
Despite his reputation for modesty, Dr. Nirenberg inspired generations of students and scholars who devoted their careers to studying the code of life, genetics, and neurobiology. He was not only a scientist？？？s scientist, but a mentor？？？s mentor. Over his life, he was awarded virtually every high honor reserved for science and medicine. Just last fall, in an occasion marked by a symposium in his honor, the American Chemical Society designated Dr. Nirenberg？？？s work as a National Historic Chemical Landmark.
For more information, visit
http://history.nih.gov/exhibits/nirenberg
Marshall Nirenberg Memorial Service
-
- Clinical Significance of Molecular Findings in Acute Leukemia (NIH Only)
-
- - Clara D. Bloomfield, M.D. (2010/11/18)
- - Category : NCI CCR Grand Rounds (NIH Only)
- Clara D. Bloomfield is Distinguished University Professor at the Ohio State University (OSU) and holder of the William Greenville Pace III Endowed Chair in Cancer Research. She is the inaugural OSU Cancer Scholar and Senior Advisor to the OSU Comprehensive Cancer Center and The Arthur G James Cancer Hospital and Richard J. Solove Research Institute. Prior significant academic administrative positions include Chair of the Department of Medicine at Roswell Park Cancer Institute and Chief of the Division of Oncology at the State University of New York at Buffalo (1989-1997), Director of the Division of Hematology and Oncology at OSU (1997-2001), and Director of the OSU Comprehensive Cancer Center (1997-2003).
Dr. Bloomfield is an internationally recognized clinical scientist whose more than 35 years of groundbreaking research on adult leukemia and lymphoma, described in over 885 publications, have changed the way we think about these diseases and treat these patients. She pioneered the use of biologic characteristics of neoplastic cells for selecting appropriate curative therapy for individual patients. She first suggested and demonstrated that adults with acute leukemia, including the elderly, could be cured with chemotherapy. She first showed that certain groups of leukemia patients, defined in particular by genetic characteristics of the leukemia, required intensive therapy for cure, while others could be cured with standard approaches. Her study of chromosomes in leukemia and lymphoma has had enormous impact by aiding in identifying genes involved in development of these disorders and the application of this information for effective therapy for individual patients. She first identified several now classic chromosome changes in leukemia and lymphoma, for example, the Philadelphia chromosome in acute lymphoblastic leukemia and rearrangement of 16q22 in acute myeloid leukemia (AML). She is considered the world？？？s authority on how chromosome changes influence treatment and outcome in adult acute leukemia.
Recently Dr. Bloomfield has been the driving force in identifying novel molecular prognostic markers in AML. She helped initiate the first use of gene array analysis of transcription to classify leukemias and continues to do pioneering work in the area of gene and microRNA expression profiling. Her work has resulted in the current World Health Organization (WHO) classification of hematologic malignancies, and the use of genetics for individualized therapy in leukemia and lymphoma in the most widely used cancer clinical guidelines--those of the National Comprehensive Cancer Network (NCCN)--and for AML the European LeukemiaNet guidelines. Dr. Bloomfield has made extensive contributions to national and international professional organizations, including serving on the board of directors of the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR) and the NCCN and chairing the National Cancer Institute (NCI) Division of Cancer Treatment？？？s Board of Scientific Counselors. She served as 1 of the 3 chairs of the NCI Progress Review Group which outlined the national agenda for research in Leukemia, Lymphoma and Myeloma. She chaired the last two WHO Clinical Advisory Committees for Neoplastic Diseases of the Hematopoietic and Lymphoid Systems. She has served as President of the Association for Patient Oriented Research and President of the International Association for Comparative Research in Leukemia and Related Diseases. The recipient of many prestigious honors, Dr. Bloomfield is an elected member of the Institute of Medicine of the National Academy of Sciences, and recipient of the 2004 Joseph H. Burchenal Clinical Research Award of the AACR, the 2006 ASCO Distinguished Service Award for Scientific Achievement, the 2008 Henry M. Stratton Medal of the American Society of Hematology, and the 2009 David A. Karnofsky Memorial Award of the ASCO.
NCI？？？s Center for Cancer Research (CCR) Grand Rounds is a weekly lecture series addressing current research in clinical and molecular oncology. Speakers are leading national and international researchers and clinicians proposed by members of the CCR Grand Rounds Planning Committee and others within the CCR community and approved by the CCR Office of the Director. Lectures occur every Tuesday from 8:00 to 9:00 a.m. in Lipsett Amphitheater in the Clinical Center building on the NIH campus September through July with exceptions around holidays and major cancer meetings. CME credit available via sign-up sheets in the lecture hall and at designated video-bridge sites only.
Clinical Significance of Molecular Findings in Acute Leukemia (NIH Only)
-
- Secretarys Advisory Committee on Genetics, Health, and Society (SACGHS) October 2010 - Day 1
-
- - Office of the Director (2010/11/18)
- - Category : Secretarys Advisory Committee on Genetics, Health, and Society
- OBA manages the Secretarys Advisory Committee on Genetics, Health, and Society (SACGHS), which advises the Secretary of Health and Human Services on the broad range of human health and societal issues raised by the development and use and potential misuse of genetic technologies.
Extraordinary scientific advances in biology, human genetics, and genomics are speeding the development of new technologies to predict, diagnose, and treat disease. These technologies, however, have medical, ethical, legal, and social implications and their integration into clinical and public health practice must be done with great care.
http://oba.od.nih.gov/SACGHS/sacghs_home.html
Secretarys Advisory Committee on Genetics, Health, and Society (SACGHS) October 2010 - Day 1
-
- NIAID/DAIDS HIV/AIDS Strategic Working Group (SWG) - Day 1 (NIH Only)
-
- - NIAID/DAIDS (2010/11/18)
- - Category : NIAID Council (NIH Only)
- The NIAID/DAIDS HIV/AIDS SWG provides the DAIDS expert advice on the scientific priorities for high resource, high impact studies and important cross-cutting scientific issues related to NIAIDs funded HIV/AIDS clinical trials networks.
NIAID/DAIDS HIV/AIDS Strategic Working Group (SWG) - Day 1 (NIH Only)
-
- Fair Subject Selection & Recruitment, Undue Influence and Coercion - 2010 (Session 4)
-
- - Dave Wendler and Alan Wertheimer (2010/11/18)
- - Category : Bioethics
- Ethical and Regulatory Aspects of Clinical Research
Course Objectives
By the end of this course, participants will be able to:
Utilize a systematic framework for evaluating the ethics of a clinical research protocol.
Apply appropriate codes, regulations, and other documents governing the ethical conduct of human subject research to their own research.
Discuss controversial issues relating to human subject research, including Phase 1 research, randomization, children in research, international research, etc.
Identify the critical elements of informed consent and strategies for implementing informed consent for clinical research.
Describe the purpose, function, and challenges of IRBs.
Appreciate the experience of human subjects who have participated in research protocols.
For more information, visit
http://www.bioethics.nih.gov/hsrc/index.shtml
Fair Subject Selection & Recruitment, Undue Influence and Coercion - 2010 (Session 4)
-
- Great Teachers: Molecular Approaches for Preventing Opportunistic Healthcare Associated Infections
-
- - John E. (Jack) Edwards, Jr, MD, UCLA (2010/11/18)
- - Category : Clinical Center Grand Rounds
- Contemporary Clinical Medicine: Great Teachers
Molecular Approaches for Preventing Opportunistic/Healthcare Associated Infections
John E. (Jack) Edwards, Jr, MD, Chief, Division of Infectious Diseases, Harbor/UCLA Medical Center, Professor of Medicine, David Geffen School of Medicine at UCLA
Great Teachers: Molecular Approaches for Preventing Opportunistic Healthcare Associated Infections
-
- Methylselenocysteine and Colon Cancer
-
- - Dr. Youcef Rustum, Roswell Park Cancer Institute (2010/11/18)
- - Category : OCCAM Monthly Lecture Series
- The NCIs Office of Cancer Complementary and Alternative Medicine (OCCAM) invites you to view its monthly lecture series.
With the goal of informing the National Cancer Institute (NCI) community about the variety of ongoing research in cancer and complementary and alternative medicine (CAM), NCIs Office of Cancer Complementary and Alternative Medicine (OCCAM) has created a monthly lecture series on cancer CAM. These hour long lectures, occurring from 10 a.m. - 11 a.m. on the second Wednesday of each month, will feature a fifty minute presentation on a cancer CAM topic and allow ten minutes for questions.
For more information, visit
http://www.cancer.gov/cam/news_lectures.html
Methylselenocysteine and Colon Cancer
-
- Cost-Effectiveness Analysis in U.S. Health Care: Trends, Myths and Future Directions
-
- - Peter J. Neumann, ScD, Tufts Medical Center (2010/11/18)
- - Category : BSSR Lecture Series
- Cost-effectiveness analysis offers decision-makers a structured, rational approach in order to improve the return on resources expended.
In this talk, Dr. Neumann will examine the potential contributions of cost-effectiveness analysis to the development and implementation of public policies, trends in the use of cost-effectiveness analysis in the U.S., and where the field may be heading in light of the recently enacted Patient Protection and Affordable Care Act (PPACA).
Cost-Effectiveness Analysis in U.S. Health Care: Trends, Myths and Future Directions
-
- PSC All Hands Meeting - October 2010 (HHS Only)
-
- - PSC Director Paul Bartley (2010/11/18)
- - Category : PSC Programs (HHS Only)
- Fourth Quarter Update
PSC All Hands Meeting - October 2010 (HHS Only)
-
- Experimental Evolution: 50,000 Generations in the Life of E. coli
-
- - Dr. Richard Lenski, Ph.D., Michigan State University (2010/11/18)
- - Category : Wednesday Afternoon Lectures
- Most evolutionary studies are based either on fossils or patterns of similarity and differences among living organisms. However, evolution is an on-going process, and therefore it can also be studied experimentally in those organisms with short generations. To that end, 12 initially identical populations of E. coli have been maintained in a simple environment since 1988, during which time the cells have undergone more than 50,000 generations. Two goals of this long-term experiment have been to investigate the dynamics of evolutionary change and to examine the reproducibility of outcomes. We have quantified the extent of adaptation by natural selection, documented increasing ecological specialization over time, observed the rise of mutator phenotypes, and even seen the origin of a new function that transcends the usual definition of E. coli as a species. We have pursued genetic approaches to find the underlying mutations responsible for these changes, including several that affect major regulatory networks. We have recently sequenced complete genomes to find all of the mutations present in a temporal series of clones, and these genomic data provide new insights into the coupling of phenotypic and genomic evolution.
The NIH Directors Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide.
Experimental Evolution: 50,000 Generations in the Life of E. coli
-
- Neutralizing antibody targets, viral escape, and B cell dysfunction in HIV-1 infection
-
- - Cynthia Derdeyn, Emory University (2010/11/18)
- - Category : Immunology
- Dr. Cynthia Derdeyn is working at the forefront of HIV vaccine research. After a post-doctoral fellowship in the laboratory of Dr. Ronald Collman at the University of Pennsylvania, Dr. Derdeyn teamed up with Dr. Eric Hunter at the University of Alabama at Birmingham where they initiated a translational research program aimed toward understanding the dynamics of HIV-1 sexual transmission. Their efforts led to the seminal discovery of an HIV-1 ？？？genetic bottleneck？？？ at the time of transmission. Dr. Derdeyn is currently an Associate Professor of Pathology and Laboratory Medicine at Emory University. Her laboratory is exploring the immune response to HIV in the earliest stages of infection following transmission, and she is delineating the mechanisms of viral immune escape. The results of her recent work are fascinating and provide valuable new insights related to the design of HIV envelope-based immunogens.
The Immunology Interest Group
Neutralizing antibody targets, viral escape, and B cell dysfunction in HIV-1 infection
-
- NIAID/DAIDS HIV/AIDS Strategic Working Group (SWG) - Day 2 (NIH Only)
-
- - NIAID/DAIDS (2010/11/18)
- - Category : NIAID Council (NIH Only)
- The NIAID/DAIDS HIV/AIDS SWG provides the DAIDS expert advice on the scientific priorities for high resource, high impact studies and important cross-cutting scientific issues related to NIAIDs funded HIV/AIDS clinical trials networks.
NIAID/DAIDS HIV/AIDS Strategic Working Group (SWG) - Day 2 (NIH Only)
-
- Enrolling Pregnant Women: Issues in Clinical Research
-
- - Office of Research on Womens Health, NIH (2010/11/18)
- - Category : Womens Health
- General Statement for Online Registration Page
？？？Pregnant women get ill, sick women get pregnant.？？？ Clinicians have meager evidence on which to base treatment of pregnant women. Clinical research investigates mechanisms of human disease, and tests therapeutic interventions. However, pregnant women are often excluded from clinical studies, and few studies are designed to address health concerns and questions relevant to pregnant women. This results in a lack of evidence to inform health care and treatment decisions. The Office of Research on Women？？？s Health (ORWH) is convening this forum to address the ethical/Institutional Review Board (IRB) and recruitment issues that investigators face in the conceptualization, initiation, and conduct of clinical research studies enrolling pregnant women.
The goal of this forum is to challenge the audience to address gaps in knowledge about medical treatment and pregnancy, to increase the evidence base on the inclusion of pregnant women in clinical research, and to conduct appropriate scientifically and ethically designed clinical research. Medical ethicists, clinical investigators, academic researchers, and those with an interest in and concern about clinical research in women, will provide information related to risk perception, risk reasoning, and the ethics of balancing risks and benefits in the clinical arena. Additionally, presenters will share examples of challenges and strategies for overcoming barriers to clinical research in treating pregnant women with chronic or infectious diseases, or on the evaluation of preventive measures such as vaccines in pregnancy. This information is intended to guide the development of new protocols, enrich interactions with local IRBs, enhance the formulation of recruitment plans, and facilitate the conduct of clinical research in pregnant women.
Enrolling Pregnant Women: Issues in Clinical Research
-
- GMAC - FY2011 NIH Update and Financial Systems Integration (HHS Only)
-
- - Marsha Hahn, Carol Wigglesworth, Stacey Kocher and Cathy Walker (2010/11/18)
- - Category : GMAC (HHS Only)
- This session will prepare attendees for the latest NIH policy and administrative changes affecting grantees and NIH Grants Management staff. Includes a myriad of information: hESCs, ARRA, FCOI, eSNAP, MYF, My NCBI, xTrain, FFR, and the new Grants Policy Statement. Changes to the GM system related to the new ？？？hard funds control？？？ requirements will also be discussed, as well as a high level description of the requirements NIH must adhere to, followed by a detailed comparison of current steps to issue an award versus steps with funds control engaged.
GMAC - FY2011 NIH Update and Financial Systems Integration (HHS Only)
-
- Psychological stress and sudden cardiac death
-
- - Dr. Rachel Lampert (2010/11/18)
- - Category : NCCAM Lectures
- The Complementary and Integrative Medicine Consult Service lecture series sponsored by NCCAM provides NIH clinical center staff with opportunity to learn more about how the integration of various complementary and alternative medicine treatments can affect approaches in the research and practice for medicine
Psychological stress and sudden cardiac death
-
- Identifying and Characterizing Individual Concepts from their fMRI Signatures: From Concrete Nouns to Numbers to Social Interactions
-
- - Marcel Just, PhD, Carnegie Mellon University (2010/11/18)
- - Category : Neuroscience
- Dr. Justs research examines a variety of understanding processes involving visual thinking, language comprehension and problem-solving processes. To find out what goes on in a persons mind during such thinking, their lab uses several methodologies, such as functional brain imaging, reaction time studies, verbal protocol analysis, and eye movement monitoring during comprehension and visual thinking. The experiments determine the nature of the on-line psychological processes that occur during understanding and thinking. The research examines the thinking of both normal subjects as well as patients with brain damage, to determine the organization of the underlying cognitive mechanisms. The various performance measures are used to construct theoretical models, often expressed in computational terms, that perform the same task and exhibit similar performance characteristics as human subjects.
The specific topics that their research addresses include sentence and text comprehension, coordinated comprehension of text and diagrams, and the role of working memory in comprehension and problem-solving, mental kinematics and mental models of dynamic events. In addition to studying various kinds of understanding, they also examine why individuals differ in the strategies and cognitive resources that they bring to bear on a task, attempting to explain why some people are better thinkers than others. Since early 1995, they have been using functional magnetic resonance imaging (fMRI) to study sentence comprehension and spatial thinking. The early part of this work has not only found the network of brain areas that become active during various language and visual tasks, but has also begun to relate the amount of brain activity to the amount of cognitive processing. fMRI research has become another tool for addressing the nature of understanding (linguistic and visual), directly assessing brain function during task performance.
NIH Neuroscience Seminar Series
Identifying and Characterizing Individual Concepts from their fMRI Signatures: From Concrete Nouns to Numbers to Social Interactions
-
- Epithelial Stem Cell and Regenerative Medicine
-
- - Michele De Luca, MD, University of Modena (2010/11/18)
- - Category : Special
- Michele De Luca is Full Professor of Biochemistry, University of Modena and Reggio Emilia, and Director of the Centre for Regenerative Medicine and the Department of Stem Cells and Regenerative Medicine of the same University. He is Scientific Director of Holostem Terapie Avanzate S.r.l. Prof. De Luca was Scientific Director of the Veneto Eye Bank Foundation (2002-2007), Director of the Laboratory of Tissue Engineering at the Istituto Dermopatico dell？？？Immacolata, Rome (1996-2002), Deputy Head, Laboratory of Cell Differentiation, Istituto Nazionale per la Ricerca sul Cancro, Genova (1992-1995), Group Leader in the same Institute (1986-1992), Visiting Scientist at the Department of Cell Biology, Harvard Medical School, Boston (1985), Fogarty Fellow at the National Institutes of Arthritis, Diabetes, Digestive and Kidney Diseases (NIADDK), National Institutes of Health (NIH), Bethesda (1982-1985).
He graduated M.D. in 1980 and obtained a Specialty in Endocrinology in 1984. He is founding member of International Ocular Surface Society, member of numerous scientific societies and member of national and international committees. He is author of more than 110 scientific publications in major international journals and author of 4 international patents. He was invited lecturer in more than 120 international meetings and symposia. He was born in Savona, Italy, May, 17, 1956.
Epithelial Stem Cell and Regenerative Medicine
-
- TRACO: HIV and Imaging
-
- - F. Maldarelli and P. Choyke (2010/11/18)
- - Category : TRACO
- For more information, visit
http://ccr.cancer.gov/careers/traco.asp
TRACO: HIV and Imaging
-
- Comparative Effectiveness and Personalized Medicine: An Essential Interface (Day 1)
-
- - National Institutes of Health, Agency for Healthcare Research and Quality, ECRI Institute (2010/11/18)
- - Category : Conferences
- A conference on the status of comparative effectiveness research and its use in policy and practice.
The senior leadership of ECRI Institute1, NIH, AHRQ, the Kaiser Permanente Institute for Health Policy, Health Affairs, the Milbank Memorial Fund, and the Leonard Davis Institute of Health Economics at the University of Pennsylvania invite you to a major conference on the interface between personalized medicine and comparative effectiveness research. This meeting will be convened on October 19th and 20th, 2010, on the campus of the National Institutes of Health in Bethesda, Maryland.
Drs. Francis Collins, Director of NIH, and Carolyn Clancy, Director of AHRQ, are among our many distinguished presenters. The conference sessions, over a day and a half, are designed to be understandable and useful to a range of healthcare constituencies. The agenda will have significant time devoted to dialog with the audience and for you to meet the speakers.
With the advent of healthcare reform, our nation will be embarking on an unprecedented effort to determine which health care intervention works best for the treatment of a given condition or disorder. The Patient Protection and Affordable Care Act emphasizes the importance of comparative effectiveness research in order to evaluate clinical outcomes across study populations. It also acknowledges the key role of personalized medicine in ensuring the capacity to identify both individual and subgroup differences within populations. The addition of personalized medicine will help clinicians and patients better predict which intervention will deliver the optimal treatment to the appropriate patient at the right time.
This meeting explores two critical streams of scientific inquiry in order to better align evidentiary, infrastructure and database needs, to highlight research challenges, and to brainstorm about regulatory, ethical and societal factors affecting both fields. Our aim is to forge new synergies capable of generating innovation in the course of healthcare reform which will result in enhanced health outcomes for the American people.
Comparative Effectiveness and Personalized Medicine: An Essential Interface (Day 1)